USA based genetic testing brand, Progenesis enters the Indian market. Loktej Business, Regional News
[ad_1]
USA based global renowned genetic testing brand, Progenesis has officially entered the Indian market with its first genetic laboratory in New Delhi and an AI & Bioinformatics data center in Chennai.
The launch event held today, which saw the presence of leading health experts, physicians and researchers from across the country, marks an important milestone for Progenesis.
Progenesis has earned international accolades for its groundbreaking genetic testing solutions, particularly in the area of in vitro fertilization (IVF) treatments. The brand’s commitment to advancing breeding genetics in India is underlined by cutting-edge technology, unparalleled accuracy and dedication to customer-centric services.
Expressing his excitement at the launch event, Dr. Nabil Arrach, Founder and CEO of Progenesis, said, “We are thrilled to bring Progenesis to India, a land of immense opportunities and possibilities. While our first lab has been set up in Delhi, we aim to establish a diversified market presence by reaching out to Tier 2 and 3 markets across the country.”
Progenesis, a technology strong lab testing brand aims to raise awareness about genetic diseases and disorders by leveraging advanced technologies including Artificial Intelligence to provide non-invasive and accurate results in the Indian market.
Taking a step towards digital innovation, Progenesis has introduced the first online medical portal for preimplantation genetic testing, which streamlines the testing process for convenience and accessibility.
Addressing opportunities in the Indian market, experts discussed the huge potential in the Indian market for genetic testing, especially in the area of reproductive health.
“The brand aims to collaborate with local healthcare providers, fertility clinics and medical practitioners to expand its footprint and make advanced genetic testing solutions more accessible to a broader audience,” said Dr. Nabil Arrach.
[ad_2]
Source link
